You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Dow

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Norethindrone Acetate And Ethinyl Estradiol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000897 A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00229996 Medical Treatment of Endometriosis-Associated Pelvic Pain Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 2004-07-01 The Specific Aim of this project is to compare the efficacy and cost-effectiveness of continuous oral contraceptives versus leuprolide/norethindrone in the treatment of endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized, double-blind, trial of women with chronic pelvic pain who have been diagnosed with endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a 12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse than leuprolide/norethindrone, and that treatment with oral contraceptives is more cost-effective.
NCT00338052 Study of Bleeding With Extended Administration of an Oral Contraceptive Completed Warner Chilcott Phase 2 2006-06-01 This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.
NCT00350480 Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial Completed Kaiser Permanente N/A 2003-04-01 To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera) and a multidose, monophasic combination oral contraceptive in the treatment of hemodynamically stable women with non-gestational, acute uterine bleeding.
NCT00391807 Study of Safety and Efficacy of an Oral Contraceptive Completed Warner Chilcott Phase 3 2006-11-01 This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.
NCT00932321 Study of Safety and Efficacy of an Oral Contraceptive Completed Warner Chilcott Phase 3 2004-01-01 This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.
NCT02103569 Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 Completed Bristol-Myers Squibb Phase 1 2014-04-01 The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive agent.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Norethindrone Acetate And Ethinyl Estradiol

Condition Name

Condition Name for Norethindrone Acetate And Ethinyl Estradiol
Intervention Trials
Contraception 3
Polycystic Ovary Syndrome 1
Hepatitis C 1
Pelvic Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Norethindrone Acetate And Ethinyl Estradiol
Intervention Trials
Endometriosis 1
Polycystic Ovary Syndrome 1
HIV Infections 1
Hepatitis C 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Norethindrone Acetate And Ethinyl Estradiol

Trials by Country

Trials by Country for Norethindrone Acetate And Ethinyl Estradiol
Location Trials
United States 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Norethindrone Acetate And Ethinyl Estradiol
Location Trials
California 6
Florida 6
Washington 4
North Carolina 4
Virginia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Norethindrone Acetate And Ethinyl Estradiol

Clinical Trial Phase

Clinical Trial Phase for Norethindrone Acetate And Ethinyl Estradiol
Clinical Trial Phase Trials
Phase 3 5
Phase 2 1
Phase 1 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Norethindrone Acetate And Ethinyl Estradiol
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 3
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Norethindrone Acetate And Ethinyl Estradiol

Sponsor Name

Sponsor Name for Norethindrone Acetate And Ethinyl Estradiol
Sponsor Trials
Bristol-Myers Squibb 3
Warner Chilcott 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Norethindrone Acetate And Ethinyl Estradiol
Sponsor Trials
Industry 7
Other 6
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Moodys
AstraZeneca
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.